Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences Co., Ltd. reported on the deposit and actual usage of funds for the first half of 2024, in compliance with various regulatory requirements and guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The company’s board of directors assures the accuracy and completeness of the announcement, taking responsibility for the truthfulness of the information provided. This announcement follows the company’s participation in pharmaceutical and biological product briefings and details the utilization of self-owned funds for staff payments and designated project expenditures.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.
